Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Spotlight Therapeutics

26118 Research Place
Hayward, CA 94545
USA
(510) 543-0700
Website Company Summary Management Team
Management

CEO: Mary Haak-Frendscho (1/31/2019)
Technology: Mark Knuth (1/31/2020) ; Peter Cameron ; Mary Janatpour (10/31/2019)
Business Development: Cheng Li
Former Employees: Hari Jayaram
Board

Outside board: (May no longer be on the board) Blake Byers (GV General Partner) Antoine Yver (Daiichi Sankyo EVP Head of Oncology R&D)
Company

Business description: Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies. Spotlight's proprietary technology platform TAGE (Targeted Active Gene Editors) is a new class of biologics, CRISPR effectors engineered for direct delivery in vivo, to achieve cell-selective therapeutic genome editing. Spotlight's pipeline is advancing its modular programmable CRISPR effectors towards clinical studies in immuno-oncology, ophthalmic diseases and hemoglobinopathies. The company is headquartered in Hayward, California. For more information, please visit www.spotlighttx.com.
Capital

Rounds: 4
Recent Fundings: Mar 2022   Nov 2020
Capital raised: 80.7M
Last Round: 36.5M
Ownership: Private  
VCs include: GV Emerson CollectiveMagnetic Ventures;  Foothill Ventures ;  DNA Capital;  GordonMD;  EPIQ Capital

Last Tweets


 

Last Mentions


Overview
Record updated: Jul 2022
Sector: Biotech
Year Founded: 2017
Headcount: 26-50 as of Jul 2022
Rounds: 4
Recent Fundings: Mar 2022   Nov 2020
Capital Raised: 80.7M
Last Round: 36.5M
Ownership: Private